The DYNC2LI1 Knockout Jurkat Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population targeting the human DYNC2LI1 gene in a Jurkat T lymphoblast background. This loss-of-function model is ideal for investigating dynein-2-mediated retrograde transport and Hedgehog signaling. The polyclonal format minimizes clonal variability and supports reproducible bulk functional analyses. Efficient gene disruption is achieved via CRISPR/Cas9 technology.
Jurkat cells are an immortalized human T lymphoblast cell line derived from the peripheral blood of a 14-year-old boy with acute T-cell leukemia. These suspension cells express the interleukin-2 receptor but do not secrete IL-2, making them a classic model for T-cell signaling, apoptosis, and HIV infection studies. Their ease of culture and suitability for transfection, flow cytometry, and high-content imaging facilitate diverse experimental workflows.
DYNC2LI1 encodes a light intermediate chain of the cytoplasmic dynein-2 complex, which powers retrograde intraflagellar transport (IFT) essential for primary cilium function and Hedgehog signal transduction. It associates with core partners DYNC2H1, WDR34, and WDR60, along with IFT-A and IFT-B complexes, to mobilize ciliary cargo. Expression is regulated by RFX transcription factors and Hedgehog pathway activation. Disruption blocks GLI transcription factor (GLI1/2/3) processing downstream of SHH, PTCH1, and SMO, impairing ciliary membrane protein localization and pathway output.
Although Jurkat cells lack primary cilia, this knockout model uniquely permits exploration of non-ciliary DYNC2LI1 functions, such as potential involvement in cytoplasmic dynein activity or cytoskeletal organization. It also serves as a stringent negative control for ciliary studies. The model is valuable for investigating ciliopathy mechanisms, including short-rib polydactyly syndrome type 2A (Jeune syndrome) and asphyxiating thoracic dystrophy, in a non-ciliated context.
Researchers can use these cells for Hedgehog pathway analysis by RT-qPCR of GLI target genes, or assess dynein complex integrity via co-immunoprecipitation and Western blotting. Flow cytometry enables cell cycle and apoptosis profiling, while RNA-seq reveals transcriptome-wide changes. The polyclonal pool is well-suited for high-throughput screens and bulk biochemical assays, including proliferation studies. For further information or a quotation, please contact Ascent Research.
